Vaxxinova US has received approval for a combination E.coli-SE vaccine developed to reduce erosive colibacillosis mortality and effectively suppress systemic and intestinal colonization with Salmonella Enteritidis.

According to Dr. Jim Sandstrom, Managing Director of Vaxxinova US, the Vaxxon® SRP® E.coli-SE vaccine applies innovative SRP® technology. Lipopolysaccharides (LPS) present in conventional oil-emulsion bacterins that represent endotoxins are removed from the vaccine during manufacture. Siderophore receptor proteins serve as immunogens, stimulating both cellular and humoral immune response.

Sandstrom added, “The removal of the LPS reduces the risk for adverse effects commonly observed with whole-cell bacterins.”

 For additional information on Vaxxon® SRP® vaccines, access the company website, www.Vaxxinova.US.com.